About me
Dr. Shook was appointed Chief Medical Officer in 2023 and leads Nkarta’s global clinical development and regulatory operations. He has more than 10 years of clinical research and development experience and has authored dozens of scientific publications covering areas including the quantitation of minimal residual disease in acute myeloid leukemia, stem cell transplantation, as well as NK cell and T cell therapies for hematologic malignancies and solid tumors. Dr. Shook joined Nkarta in June 2020 and most recently served as Vice President of Clinical Development. Prior to joining Nkarta, he led multiple first-in-human cell therapy clinical trials, including pioneering the use of CD19 CAR NK cells. He was a fellow, fellowship director and faculty member at St. Jude Children’s Research Hospital, where he conducted research in the laboratory of Dario Campana, MD, PhD, Nkarta’s scientific founder.
Dr. Shook received his medical degree from The Johns Hopkins University School of Medicine and his bachelor’s degree in molecular biology from Purdue University. He is board certified in Pediatric Hematology & Oncology and General Pediatrics.